This website uses cookies.
By continuing to use this website, you consent to our use of these cookies. Read more about our use of cookies
This website uses cookies.
By continuing to use this website, you consent to our use of these cookies. Read more about our use of cookies
Joint arthropathy in primary prophylaxis develops subtly over many years, the ankle joints being the first and most severely affected5
rFVIII, recombinant Factor VIII.
References
1. Nijdam A, Foppen W, van der Schouw YT, Mauser-Bunschoten EP, Schutgens RE, Fischer K. Long-term effects of joint bleeding before starting prophylaxis in severe haemophilia. Haemophilia 2016 Nov;22(6):852–8.
2. Poon M-C, Lee A. Individualized prophylaxis for optimizing hemophilia care: can we apply this to both developed and developing nations? Thromb J. 2016 Oct 4;14(Suppl 1):32.
3. Den Uijl I, Biesma D, Grobbee D, Fischer K. Turning severe into moderate haemophilia by prophylaxis: are we reaching our goal? Blood Transfus. 2013 Jul;11(3):364–9.
4. Schrijvers LH, Beijvelt-van der Zande M, Peters M, Lock J, Cnossen MH, Schuurmans MJ, et al. Adherence to prophylaxis and bleeding outcome in haemophilia: a multicentre study. Br J Haematol. 2016;174:454–60.
5. Oldenburg J. Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens. Blood. 2015 Mar 26;125(13):2038–44.
6. Carcao M, Hilliard P, Escobar MA, Solimeno L, Mahlangu J, Santagostino E. Optimising musculoskeletal care for patients with haemophilia. Eur J Haematol. 2015 Dec;95(Suppl 81):11-21.
7. Oldenburg J, Pasi J, Pabinger I, Nolan B, Kulkarni R, Blanchette V, et al. Improvements in joint health during long-term use of recombinant factor VIII Fc fusion protein prophylaxis in subjects with haemophilia A. Poster presented at the 12th Annual Congress of the European Association for Haemophilia and Allied Disorders, 6–8 February 2019, Prague, Czech Republic. P158.
Joint arthropathy in primary prophylaxis develops subtly over many years, the ankle joints being the first and most severely affected5
rFVIII, recombinant Factor VIII.
References
1. Nijdam A, Foppen W, van der Schouw YT, Mauser-Bunschoten EP, Schutgens RE, Fischer K. Long-term effects of joint bleeding before starting prophylaxis in severe haemophilia. Haemophilia 2016 Nov;22(6):852–8.
2. Poon M-C, Lee A. Individualized prophylaxis for optimizing hemophilia care: can we apply this to both developed and developing nations? Thromb J. 2016 Oct 4;14(Suppl 1):32.
3. Den Uijl I, Biesma D, Grobbee D, Fischer K. Turning severe into moderate haemophilia by prophylaxis: are we reaching our goal? Blood Transfus. 2013 Jul;11(3):364–9.
4. Schrijvers LH, Beijvelt-van der Zande M, Peters M, Lock J, Cnossen MH, Schuurmans MJ, et al. Adherence to prophylaxis and bleeding outcome in haemophilia: a multicentre study. Br J Haematol. 2016;174:454–60.
5. Oldenburg J. Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens. Blood. 2015 Mar 26;125(13):2038–44.
6. Carcao M, Hilliard P, Escobar MA, Solimeno L, Mahlangu J, Santagostino E. Optimising musculoskeletal care for patients with haemophilia. Eur J Haematol. 2015 Dec;95(Suppl 81):11-21.
7. Oldenburg J, Pasi J, Pabinger I, Nolan B, Kulkarni R, Blanchette V, et al. Improvements in joint health during long-term use of recombinant factor VIII Fc fusion protein prophylaxis in subjects with haemophilia A. Poster presented at the 12th Annual Congress of the European Association for Haemophilia and Allied Disorders, 6–8 February 2019, Prague, Czech Republic. P158.
You are about to enter elocta.com.
Please select if you are a healthcare professional or a patient.
I'm a